Aeterna Zentaris (TSX:AEZS)
Historical Stock Chart
1 Year : From Mar 2017 to Mar 2018
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”)
will announce its second quarter 2017 financial and operating results
after market close on Thursday, August 10, 2017. The Company will host a
conference call to discuss these results on Friday, August 11, 2017 at
8:30 a.m. Eastern Time.
Participants may access the conference call using the following number:
201-689-8029, Confirmation #13665527. A replay of the conference call
will also be available on the Company’s website for a period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing and commercializing novel pharmaceutical therapies. We are
engaged in drug development activities and in the promotion of products
for others. We recently resubmitted an NDA to the FDA seeking approval
of MacrilenTM, an internally developed compound. The focus of
our business development efforts is the acquisition of licenses to
products that are relevant to our therapeutic areas of focus. We also
intend to license out certain commercial rights of internally developed
products to licensees in non-U.S. territories where such out-licensing
would enable us to ensure development, registration and launch of our
product candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value to
our shareholders, employees and the medical providers and patients who
will benefit from our products. For more information, visit www.aezsinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170804005689/en/
Aeterna Zentaris Inc.Michael V. Ward, 843-900-3223Chief